ArticleRenal failure2026
Biochemical phenotypes of acute kidney injury and their association with major adverse kidney events.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a heterogeneous syndrome in which conventional stratification based on serum creatinine and urine output may fail to capture the full spectrum of underlying metabolic disturbances. In a retrospective cohort study of hospitalized adults with AKI admitted to Hospital General de Mazatlán between January 2022 and July 2025, we sought to identify biochemical phenotypes associated with major adverse kidney events (MAKE). Demographic, clinical, and biochemical variables, including urea, creatinine, calcium, phosphorus, potassium, hemoglobin, albumin, and pH, were standardized using z-scores and clustered using k-means analysis. The primary outcome was MAKE, defined as in-hospital mortality or new requirement for kidney replacement therapy (KRT). Among 797 patients, three distinct biochemical phenotypes were identified: Phenotype 1, characterized by relatively preserved biochemical parameters; Phenotype 2, defined by anemia and hypocalcemia; and Phenotype 3, marked by severe metabolic derangements. Phenotype 3 exhibited the most severe kidney dysfunction and metabolic instability, including anemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and acidosis, and was strongly associated with MAKE (odds ratio [OR] 3.39, 95% confidence interval [CI] 2.12-5.40;
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.